Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A lymphoma that arises from the structures of the orbit. Representative examples include mucosa-associated lymphoid tissue lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.
Biomarker and diagnostic research for orbit lymphoma has been reported in the published literature.
2 clinical trials registered. Interventions under study include procedural interventions and drug therapy. Pipeline includes 1 PHASE2, 1 NA. Research is primarily sponsored by academic and government institutions.
55 publications have been identified in PubMed for orbit lymphoma. Research spans Case Report / Case Series (47%), Diagnostic / Biomarker (13%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 26 |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 6:09 PM UTC
Genetic and Rare Diseases Info Center
Testing and diagnosis research | 7 | 13% |
Research summaries | 6 | 11% |
Disease patterns and progression | 6 | 11% |
Clinical study results | 5 | 9% |
Laboratory research | 4 | 7% |
New treatment approaches | 1 | 2% |
Reddy M (2026). [PMID: 40247460](https://pubmed.ncbi.nlm.nih.gov/40247460/). *Clinical nuclear medicine*. [Case Report / Case Series]
Liu H (2026). [PMID: 41610699](https://pubmed.ncbi.nlm.nih.gov/41610699/). *European journal of radiology*. [Diagnostic / Biomarker]
Jung R (2026). [PMID: 41495378](https://pubmed.ncbi.nlm.nih.gov/41495378/). *Veterinary medicine and science*. [Basic Science / Preclinical]
Gutierrez Albenda D (2026). [PMID: 42037939](https://pubmed.ncbi.nlm.nih.gov/42037939/). *Cureus*. [Case Report / Case Series]
Agarwal A (2026). [PMID: 41949897](https://pubmed.ncbi.nlm.nih.gov/41949897/). *Orbit*. [Case Report / Case Series]
Liu S (2026). [PMID: 41949825](https://pubmed.ncbi.nlm.nih.gov/41949825/). *Orbit*. [Case Report / Case Series]
Zong M (2026). [PMID: 41959924](https://pubmed.ncbi.nlm.nih.gov/41959924/). *Front Oncol*. [Review / Meta-Analysis]
Pojda-Wilczek D (2026). [PMID: 42078311](https://pubmed.ncbi.nlm.nih.gov/42078311/). *Cancer Diagn Progn*. [Case Report / Case Series]
Maruyama T (2026). [PMID: 42049442](https://pubmed.ncbi.nlm.nih.gov/42049442/). *In Vivo*. [Review / Meta-Analysis]
Ren S (2026). [PMID: 42063771](https://pubmed.ncbi.nlm.nih.gov/42063771/). *Front Med (Lausanne)*. [Epidemiology / Natural History]
AI-curated news mentioning orbit lymphoma
Updated Oct 18, 2026
A case study highlights the presence of occult lymphoma in a 38-year-old woman diagnosed with hemophagocytic lymphohistiocytosis. This discovery may provide insights into the complex relationship between these two conditions.
Caribou Biosciences will halt its CAR-T therapy development and lay off staff due to an inability to secure funding for its late-stage lymphoma trial. The company is now exploring strategic alternatives to navigate the challenging funding climate.
A recent case series published in PubMed highlights instances of spontaneous regression in vitreoretinal lymphoma lesions, contributing to the understanding of this rare condition. The findings may influence future research and treatment approaches for lymphoma.
A study published in PubMed reveals specific molecular profiling of secreted rheumatoid factors in patients with Sjögren's disease who also have lymphoma. This research could enhance understanding of the disease's pathology and inform future therapeutic strategies.
Roche partners with Simcere Zaiming in a $1.5 billion deal to develop a T cell engager targeting B cell-mediated diseases, including lymphoma and autoimmune conditions. This collaboration aims to leverage innovative therapies for a range of serious health issues.